The repayment percentages confirmed by the UK government under the statutory scheme for branded medicines are “significantly out of line with any other comparable country and will have a real impact on NHS patients and the UK’s ambitions for the life sciences sector,” according to David Watson, executive director of patient access at the Association of the British Pharmaceutical Industry (ABPI).
The UK Department of Health and Social Care (DHSC) confirmed earlier this month that it plans to raise the percentage of sales that companies pay back under the statutory scheme from 10.9% to 14.3% in 2022 and to 24.4% in 2023, following the completion of a consultation that ran from 14 March to 26 April
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?